Triple treatment for cervical Ca shows great promise

Article

Adding hyperthermia to standard chemoradiotherapy for advanced cervical carcinoma seems to boost the positive effects of treatment without adding any negative effects, according to analysis of three phase 2 studies.

Adding hyperthermia to standard chemoradiotherapy for advanced cervical carcinoma seems to boost the positive effects of treatment without adding any negative effects, according to analysis of three phase 2 studies.

Most of 68 women with a median age of 45 years and stage IIB, III, or IVA disease received a biologically effective radiotherapy and brachytherapy dose of 86.7 gray or higher, at least four courses of 40 mg/m2 weekly cisplatin, and four weekly sessions of locoregional hyperthermia.

Ninety percent of the women achieved complete remission. After a median of 18 months, 84% of the women remained alive, 74% of whom were without recurrence. Toxicity was comparable to that with chemoradiotherapy alone. A phase 3 study of the triple treatment is underway.

Newsletter

Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.

Recent Videos
Neal Barnard, MD, FACC, highlights AMA's new breast cancer prevention guidelines | Image Credit: pcrm.org.
Zachary Wagner, PhD, discusses the harms of bias in reproductive care | Image Credit: ornsife.usc.edu.
Ciera Kirkpatrick, PhD, shows how TikTok is transforming cervical cancer awareness | Image Credit: linkedin.com.
Related Content
© 2025 MJH Life Sciences

All rights reserved.